Targets USD 25 Billion Investments and 5 Lakh Jobs  

The Government of Telangana has unveiled its ambitious Next-Gen Life Sciences Policy 2026–30 at the World Economic Forum Annual Meeting in Davos, signalling its intent to rank among the world’s top five life sciences clusters by 2030.

The policy marks a strategic shift from scale-led manufacturing to value-driven, innovation-powered growth, with a sharp focus on advanced biologics, next-generation therapies, and sustainable bio-manufacturing. Telangana aims to attract USD 25 billion in investments and create 500,000 high-quality jobs over the next five years, further strengthening Hyderabad’s global standing in healthcare and life sciences.

Chief Minister A. Revanth Reddy said the global launch at Davos reflects the State’s belief that future growth in life sciences will be driven by cross-border collaboration, global capital, and shared innovation ecosystems.

The policy prioritises frontier science and advanced manufacturing platforms, including cell and gene therapies, peptides, precision fermentation, and emerging therapeutic modalities. IT & Industries Minister D. Sridhar Babu highlighted Telangana’s strong momentum, noting investments of Rs. 73,000 crore attracted over the past two years and a new target of Rs. 2 lakh crore in the next five years.

Shakthi M. Nagappan, CEO of Telangana Life Sciences, said initiatives such as the Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, and the proposed Telangana School of Life Sciences will boost early-stage innovation and build future-ready talent.

The policy will be anchored by Green Pharma City, ten Pharma Villages, expansion of Genome Valley, and a stronger Medical Devices Park, integrating sustainability measures like zero liquid discharge and net-zero operations.

Home to over 2,000 life sciences companies and a major share of USFDA-approved facilities, Telangana already supplies one-third of global vaccine demand and now aims to emerge as a global originator of advanced therapies.